Memorial Sloan Kettering pediatric oncologist Paul Meyers

Paul A. Meyers, MD

Pediatric Hematologist-Oncologist

Titles

Chief, Pediatric Sarcoma Service; Robbins Family Chair in Pediatrics; Vice Chair for Clinical Affairs

Clinical Expertise

Pediatric Oncology; Osteosarcoma; Ewing Sarcoma; Leukemias; Rhabdomyosarcoma and Other Soft Tissue Developmental Tumors of Childhood

Back to top
Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Schedule an Appointment
833-MSK-KIDS
Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Meyers accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 9/1/23)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO

First Health

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Medicare Part A&B (traditional Medicare)

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Mount Sinai School of Medicine

Residencies

Pediatrics - Mount Sinai Hospital

Fellowships

Pediatrics - Cornell Medical Center; Pediatrics - Memorial Sloan Kettering Cancer Center

Board Certifications

Pediatrics; Pediatric Hematology-Oncology

I am a pediatric oncologist with extensive experience caring for children and young adults with sarcomas. At Memorial Sloan Kettering, we treat more children and young adults with these challenging tumors than anywhere else in the country. I am proud to be part of MSK Kids, a team that takes a comprehensive approach to care. We customize a care plan for each child, with the goal of saving the lives of our young patients.

Read more

Many of our patients are teens and young adults. They are transitioning from childhood dependence on their parents to independent living. We help them maintain their independence in every way during their cancer care while still ensuring that they have the emotional and practical support of their family.

Many of the types of cancer in young adults are quite rare. Very few oncologists have experience treating them. Some young adults have a form of cancer that is seen much more commonly in children and teens. These patients need a team of specialists from multiple medical fields. They can find that level of expertise in the multidisciplinary teams at Memorial Sloan Kettering. Our specialists combine their skills and experience to come up with the most effective therapy for each individual.

I also direct clinical research to develop and assess new therapies for sarcomas. For five years I served as head of the bone sarcoma strategy group for the Children’s Cancer Group. In that role, I directed national clinical trials for osteosarcoma and Ewing sarcoma. I also conducted clinical trials for people with newly diagnosed and recurrent osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated sarcoma, and other unusual tumors that occur in children and young adults. I have much more experience treating these challenging cancers than most doctors.

In addition to caring for patients and doing research, I enjoy teaching. Memorial Sloan Kettering offers one of the most comprehensive training programs in pediatric hematology/oncology in the country. We care for a very large number of patients, and our faculty has many decades of experience. Our trainees see an unparalleled variety of clinical challenges. Fellows also have the benefit of working with faculty at nearby institutions, such as Weill Cornell Medicine and The Rockefeller University.

I have authored or co-authored more than 135 publications about sarcomas. In recognition of my work, I received the Willet E. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering in 1995. I served as president of the Connective Tissue Oncology Society, a leading academic society devoted to the study of sarcomas. I am a member of the National Cancer Institute’s Physician Data Query Pediatric Board.

I am also the founding medical director for Happiness Is Camping, a summer camp for children with cancer. Helping give these kids a respite from the rigors of cancer therapy has been an extraordinary opportunity. To see these children blossom and thrive away from the hospital environment is one of the great joys of my job.

I am proud to be part of MSK Kids, a team that takes a comprehensive approach to care.

-Dr. Meyers

Awards and Honors

  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2002-2018)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Pediatrics doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan Kettering experience and a literature review.. J Clin Oncol. 2001; 19 :870-880

Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK.. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.. Med Pediatr Oncol 2000; 35 :468-74

Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M.. Prognostic impact of INK4A deletion in Ewing sarcoma.. Cancer 2000; 89 :793-9

Read more

de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M.. Prognostic impact of P53 status in Ewing sarcoma.. Cancer 2000; 89 :783-92

Shamberger RC, Laquaglia MP, Krailo MD, Miser JS, Pritchard DJ, Gebhardt MC, Healey JH, Tarbell NJ, Fryer CJ, Meyers PA, Grier HE.. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.. J Thorac Cardiovasc Surg. 2000; 119 :1154-61

Saenz NC, Hass DJ, Meyers P, Wollner N, Gollamudi S, Bains M, LaQuaglia MP.. Pediatric chest wall Ewing sarcoma.. J Pediatr Surg. 2000; 35 :550-5

Guo W, Gorlick R, Ladanyi M, Meyers PA, Huvos AG, Bertino JR, Healey JH.. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop 1999; 365 :175-83

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA.. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 19 :2781-8

Flombaum CD, Meyers PA.. High-dose leucovorin as sole therapy for methotrexate toxicity.. J Clin Oncol 1999; 17 :1589-94

Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, Gorlick R.. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5 :621-7

Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. J Clin Oncol 1998; 16 :3016-20

Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.. J Bone Joint Surg Am. 1998; 80 :1020-33

Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol.. J Clin Oncol 1998; 16 :2452-8

Kawai A, Huvos AG, Meyers PA, Healey JH.. Osteosarcoma of the pelvis. Oncologic results of 40 patients.. Clin Orthop 1998; 348 :196-207

de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing sarcoma. J Clin Oncol 1998; 16 :1248-55

Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AG, Larson SM.. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AGThallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma, Larson SM.. Cancer 1997; 80 :1507-12

Meyers PA, Gorlick R.. Osteosarcoma. Pediatr Clin North Am. 1997; 44 :973-89

Hwang ES, Gerald W, Wollner N, Meyers P, La Quaglia MP.. Leiomyosarcoma in childhood and adolescence.. Ann Surg Oncol 1997; 4 :223-7

O’Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C.. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network.. Oncology 1996; 10 :1799-806

Terek RM, Brien EW, Marcove RC, Meyers PA, Lane JM, Healey JH.. Treatment of femoral Ewing sarcoma. Cancer 1996; 78 :70-8

Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. J Clin Oncol 1996; 14 :1526-31

Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing sarcoma, in children and young adults. J Clin Oncol 1995; 13 :2796-804

Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M.. Osteogenic sarcoma with clinically detectable metastasis at initial presentation.. J Clin Oncol 1993; 11 :449-53

Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al.. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.. N Engl J Med 1992; 326 :1301-8

Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G.. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10 :5-15

 

Publications on PubMed

Visit PubMed for a full listing of Dr. Meyers’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Paul A. Meyers discloses the following relationships and financial interests:

  • Margaux Miracle Foundation
    Provision of Services (uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: